Castle Biosciences (CSTL) Interest & Investment Income (2018 - 2026)

Castle Biosciences has reported Interest & Investment Income for 9 years, with the latest figure at $2.4 million in Q2 2026.

• Quarterly Interest & Investment Income fell 19.97% year-over-year to $2.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.8 million (down 19.4% YoY) and the FY2025 annual result came in at $11.8 million, down 8.86% from the prior year.
• Interest & Investment Income advanced to $2.4 million in Q2 2026 per CSTL's latest filing, from -$330000.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $3.4 million in Q3 2024 and troughed at -$330000.0 in Q1 2026.
• A 5-year average of $1.5 million and a median of $1.8 million in 2022 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2024: Interest & Investment Income soared 13282.35% in 2022, then slumped 662.5% in 2024.
• Over 5 years, Interest & Investment Income stood at $2.3 million in 2022, then surged by 37.1% to $3.1 million in 2023, then advanced by 8.11% to $3.4 million in 2024, then retreated by 14.12% to $2.9 million in 2025, then declined by 18.65% to $2.4 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $2.4 million, -$330000.0, and $2.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.